I know this is a bit long but very exciting news.
Photomedicine and Laser Surgery
Mary Ann Liebert, Inc., publishers is pleased to announce that due to the growing research and interest in Photobiomodulation, Photomedicine and Laser Surgery will expand its scope and title to Photobiomodulation, Photomedicine, and Laser Surgery in January 2019. We are pleased to announce that Michael R. Hamblin, PhD will join the journal as Editor-in-Chief in August 2018. Dr. Hamblin has published more papers on this topic than anyone in the field (per Web of Science).
Raymond Lanzafame, MD, who has provided strong leadership for the journal as Editor-in-Chief for over two decades, will take on the role of Executive Editor to ensure a smooth transition. We are extremely grateful to Dr. Lanzafame for his long-term commitment to the Journal and the field.
Dr. Hamblin is a Principal Investigator at the Wellman Center for Photomedicine, Massachusetts General Hospital, and an Associate Professor at Harvard Medical School. His major research interests span photodynamic therapy (PDT) and photobiomodulation. Dr. Hamblin has published more papers on this topic than anyone in the field (per Web of Science). He has published 420 peer-reviewed articles, which have had more than 31,000 citations (h-factor 89). He is Editor/Associate Editor for 10 journals and serves on several NIH Study Sections. Dr. Hamblin has authored/edited 23 textbooks on PDT and photomedicine including SPIE proceedings. Dr. Hamblin was elected as a Fellow of SPIE in 2011, received 1st Endre Mester Lifetime Achievement Award Photomedicine from NAALT in 2017, and the Outstanding Career Award from the Dose Response Society in 2018.
Dr. Hamblin is eager to take on this challenge and has provided the following Vision Statement for the Journal:
Photobiomodulation is one of the hottest growing areas in biomedical science today. The rise of the internet has led to increasing interest and demand for nonpharmaceutical, safe, and effective treatments for a wide range of human diseases and conditions. Now that the molecular and cellular mechanisms are becoming more well-understood, the field is poised to join the 21st century. For many years “low level laser therapy” struggled to gain credibility and acceptance in both the medical and general communities. There has never been a journal that was the accepted “go-to” venue to publish PBM papers, until now. To introduce the term “photobiomodulation” into the Journal title marks a sea-change, and to keep the term ‘laser” will ensure that all PBM and LLLT papers will fit in. Since PBM is growing apace, the number of citations each good-quality paper receives will also grow in concert. Therefore, I envisage the impact factor will significantly rise. Special issues, commentaries, and provocative editorials will continue to raise the profile of the Journal, accompanied by judicious use of social media, such as Twitter.
Please join me in thanking Dr. Lanzafame and welcoming Dr. Hamblin.
Chief Editorial Officer
Mary Ann Liebert, Inc., publishers